Tag: Atrial Fibrillation
Oversight of DOAC Prescribing Beneficial for A-Fib, VTE Patients
Oversight identifies errors, especially in a-fib patients, who mainly have alerts for off-label prescribing during follow-up period
Pharmacist Prescribing Can Reduce Stroke Risk in A-Fib Patients
Findings seen for pharmacist prescribing compared with usual care in older adults at high risk for stroke
Digoxin, Beta-Blockers Have Equivalent Effects on Heart Rate in A-Fib
Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test
Pulsed Field Ablation Demonstrates Favorable Safety Profile for A-Fib
No esophageal complications, pulmonary vein stenosis, persistent phrenic palsy observed; stroke was rare and death even rarer
Study Compares Rivaroxaban, Warfarin With Apixaban for Cirrhosis, A-Fib
Initiators of rivaroxaban or warfarin versus apixaban have significantly higher rates of major hemorrhage
Rare Predicted Loss-of-Function Variants, Polygenic Risk Score Linked to Risk of A-Fib
Odds ratio of 7.08 for atrial fibrillation for rare pLOF variants combined with high polygenic risk score
Disparities in Direct Oral Anticoagulant Initiation Have Declined in Recent Years
Findings seen for Black and Hispanic patients with atrial fibrillation versus White patients
A-Fib Patients Younger Than 65 Face Heightened Risk for Heart-Related Hospitalization
Findings over five years also show high burden of risk factors and comorbidities
Three-Month Blanking Period After A-Fib Ablation Should Be Shortened, Researchers Say
Two studies show recurrence within blanking period is associated with increased risk for recurrence in long term
2000-2010 to 2011-2022 Saw Increase in Lifetime Risk for A-Fib
Most frequent complication after atrial fibrillation was heart failure, with lifetime risk of more than 42 percent
